|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||56.83 - 58.01|
|52-week range||55.69 - 84.88|
|PE ratio (TTM)||14.27|
|Earnings date||5 Feb 2018 - 9 Feb 2018|
|Forward dividend & yield||1.85 (3.22%)|
|1y target est||70.80|
Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc's China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide. The deal will also help Shanghai Pharma, China's third largest drug distributor, become a leading importer of foreign medicine into the world's second-largest drug market.
Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.
Shanghai Pharmaceuticals Holding Co. is exploring further acquisitions after it beat out global buyout firms to buy Cardinal Health Inc.’s Chinese distribution business in a $1.2 billion deal.
The U.S. pharmaceutical company, which has taken a hit from falling generic-drug prices, is unloading its distribution operations as Beijing tightens oversight of the industry.
Nov 15 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd * Says its unit Century Global signs deal to acquire Cardinal Malaysia for about $557 million Source text in Chinese: http://bit.ly/2iWTXfc Further ...
Glancy Prongay & Murray LLP announces an investigation on behalf of Cardinal Health, Inc. investors concerning the Company and its officers’ possible violations of federal securities law.
Stocks that raise their dividend meaningfully every year will make you a lot of money over the long haul… provided they continue to boost their payouts, of course.
Law Offices of Howard G. Smith announces an investigation on behalf of Cardinal Health, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
Cardinal Health said CFO Mike Kaufmann will become CEO, replacing George Barrett, who will step down in January.
Solid growth at Medical Segment drove Cardinal Health's (CAH) first-quarter results. Product launches and completion of strategic acquisitions in the quarter are major positives.
The expanded complaint proposed by the states in their drug collusion probe claims some of the biggest buyers of drugs from generic manufacturers “benefit when prices are higher.”
On a per-share basis, the Dublin, Ohio-based company said it had net income of 36 cents. Earnings, adjusted for amortization costs and restructuring costs, were $1.09 per share. The results topped Wall ...
JEFFERSON CITY, Mo. (AP) — Missouri Attorney General Josh Hawley on Tuesday said he's demanding documents from three major opioid distributors that he claims didn't report suspiciously large shipments of prescription drugs.
U.S. shareholder activists are addressing a soaring death toll from opioid drug abuse, asking companies that make and distribute the painkillers to review the risks their businesses could face from their role in the sector. Leaders of a 30-fund group that includes state pension officials and religious and labor organizations plan to reveal on Monday they have begun filing shareholder resolutions at 10 companies, including distributors AmerisourceBergen Corp (ABC.N) and Cardinal Health Inc (CAH.N) and manufacturers Johnson & Johnson (JNJ.N) and Insys Therapeutics (INSY.O). Representatives of Cardinal and Insys did not immediately respond to requests for comment.
Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.
Private equity firm FountainVest Partners Co. is vying with a state-owned pharmaceutical group to acquire Cardinal Health Inc.’s Chinese distribution unit, which could fetch more than $1 billion, people ...
On July 30, 2017, Cardinal Health (CAH) completed the acquisition of Medtronic’s patient recovery business for an all-cash consideration worth $6.1 billion.
In fiscal 2017, Cardinal Health’s (CAH) Medical segment reported robust demand in areas such as surgical kitting, lab services, post acute, and medical services.
Cardinal Health’s (CAH) Specialty Solutions segment provides two types of services: upstream to pharmaceutical and biopharmaceutical manufacturers and downstream to healthcare providers.
Wall Street analysts have projected Cardinal Health’s fiscal 2018 net profit margins to be 1.0%, which will be similar to what the company reported in fiscal 2017.
For fiscal 2018, Cardinal Health (CAH) has projected mid-single-digit revenue growth on a YoY basis, partially driven by the company’s high customer retention rates.
Cardinal Health (CAH) reported revenues of $130.0 billion for fiscal 2017, which is a YoY (year-over-year) rise of 7.0%.